Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
Neukio Biotherapeutics
company
About
Neukio Biotherapeutics is a developer of allogenic immune cell therapies for treatment of cancer.
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $50M
- Industries
- Biotechnology
- Founded date
- Jan 1, 2021
- Operating Status
- Active
Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general-purpose spot immune cell products, and is committed to providing effective therapeutic drugs for cancer patients around the world.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$90M
Neukio Biotherapeutics has raised a total of
$90M
in funding over 2 rounds. Their latest funding was raised on
Sep 2, 2022 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 2, 2022 | Series A | $50M | 3 | — | — | Detail |
| Jul 29, 2021 | Angel | $40M | 1 |
Lilly Asia Ventures
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
3
Neukio Biotherapeutics is funded by 3 investors.
Yahui Precision Medicine Fund
and Kuanyu Private Equity
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Yahui Precision Medicine Fund
|
— | Series A |
Kuanyu Private Equity
|
— | Series A |
|
Lilly Asia Ventures
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
